The German Society of Infectious Diseases (DGI) has initiated the establishment of a European case registry to collect clinical data of patients with SARS-CoV-2 infection.
You may also like: Germany Joins ‘1+ Million Genomes’ Initiative
The new registry, Lean European Open Survey for SARS-CoV-2 Infected Patients (LEOSS), is aimed at providing scientists and doctors with reliable clinical data to enable them to answer numerous urgent questions, such as when do COVID-19 patients develop severe symptoms? what is the best possible treatment? or which measures have been successful up to now? Under the new initiative, all the collected data will be available to the scientific community for use in crowd-based analyses.
The first cases were submitted on 17 March, and as of 20 March there are 20 documented cases from 21 confirmed sites.
The registry is available across the EU and allows anonymous documentation, thus permitting patients who are no longer able to give their informed consent to be included in the registry. The study is self-governed by a Board of Investigators consisting of the contributing centres, with the participation of Country Coordinators and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) representatives.
The initiative has been jointly set up with the German Center for Infection Research (DZIF) and is supported by Robert Koch Institut, Data Against COVID-19 and ESCMID’s Emerging Infections Task Force.
Prof. Jörg Janne Vehreschild, DZIF scientist at the University Hospital of Cologne who is coordinating the project, noted that there was an urgent need for free anonymised data in SARS-CoV-2 research. “The availability of palpable clinical data of patients in Europe can be pivotal in providing the best care possible for the anticipated high number of cases, including those who are critically ill,” Vehreschild emphasised.
Interested study centres and data analysts are invited to participate. More information is available on the project’s website.
Image credit: LEOSS